Key points for investors:
- Acquisition and strategic positioning: Alkermes closed the mid-February acquisition of Avadel, adding LUMRYZ (once-at-bedtime sodium oxybate) and establishing an immediate commercial footprint in sleep medicine ahead of the potential launch of Alixorexton. Integration of Avadel commercial teams is progressing and the company sees LUMRYZ as a durable, growth-driving asset.
- Q1 financials and product performance: Proprietary product net sales rose 38% Y/Y to $338.1M. Notable Q1 product results: VIVITROL $112.4M (2026 guidance $460M–$480M), ARISTADA family $93.8M (guidance $365M–$385M), LYBALVI $92.4M (guidance $380M–$400M). LUMRYZ contributed approximately $72M of net revenue for the quarter (about $39.5M for the 6 weeks post-close) and Alkermes expects LUMRYZ full-year net sales of $350M–$370M (Alkermes share $315M–$335M reflecting mid-February close).
- Updated 2026 outlook & accounting refinements: CFO updated purchase price accounting refinements related to Avadel (inventory step-up and intangible amortization) that materially improved 2026 GAAP net loss and EBITDA expectations. New 2026 ranges: GAAP net loss $70M–$90M; EBITDA $105M–$135M; adjusted EBITDA unchanged and still strong. Q2 guidance: proprietary portfolio Q2 net sales $385M–$405M; adjusted EBITDA Q2 $100M–$120M.
- Cash, capital structure and shareholder returns: Ended Q1 with ~$538M cash & investments after using ~$775M of cash for the acquisition and entering $1.525B term loans due 2031. Company expects to pay down debt quickly with cash flow. Q1 repurchased ~1M shares for $28M; $172M remaining authorization.
- Costs and investment: Q1 R&D $103.3M (up vs prior year) reflecting initiation of Alixorexton Phase III (Brilliance), Vibrance-3 Phase II (IH), and Phase I work for next orexin candidates; R&D guidance Q2 $110M–$120M. SG&A Q1 included ~$55M one-time Avadel transaction-related costs; ongoing SG&A (ex-one-time) rose reflecting commercial integration.
- Orexin franchise and pipeline advancement: Alixorexton (orexin 2 receptor agonist) Phase III Brilliance program in NT1 and NT2 is open for enrollment; Vibrance-2 NT2 data to be presented in June. Vibrance-3 (IH) Phase II ongoing; top line expected Q4. Alkermes is expanding orexin development beyond hypersomnolence into ADHD (ALKS 7290: Phase Ib ongoing, ~50 patients; Phase II ~300 patients planned this summer) and fatigue (ALKS 4510: Phase IIa planned in MS and Parkinson’s later this year). Management emphasizes differentiated clinical datasets, dosing flexibility, and competitive positioning.
- Commercial expectations & competitive landscape: Management believes limited IP and few competitors make orexin pathway attractive; Lilly’s entry is cited as validation of the space. For VIVITROL, management expects durable franchise dynamics even with potential generic entrants and is modeling multiple scenarios.
- Risks & focus: Management emphasizes execution risk for Phase III programs, ongoing integration risks, and typical regulatory/clinical risks. Near-term priorities are strong commercial execution for 2026, rapid but disciplined enrollment/execution of orexin trials, and investing to expand the orexin portfolio.
Sign In
Buy ALKS
